Core Viewpoint - Reliance Global Group has increased its investment in Zcash (ZEC) as part of its Digital Asset Treasury strategy, believing that ZEC is a resilient and adaptable digital asset suitable for institutional use [1][2][3] Group 1: Investment Strategy - The additional allocation to ZEC reflects the company's view that it can play a significant role in long-term treasury management [1][2] - Reliance's decision is based on the belief that Zcash's dual architecture offers both transparency and privacy, making it appealing for organizations in regulated environments [2][3] - The company anticipates that as digital assets evolve, there will be a greater focus on balancing confidentiality with compliance, positioning Zcash favorably in this context [3] Group 2: Management Insights - Moshe Fishman, Director of Insurtech, emphasized that ZEC's combination of optional transparency and a practical privacy model provides institutions with necessary flexibility while adhering to governance and compliance standards [3] - Ezra Beyman, Chairman and CEO, stated that privacy is a crucial aspect of modern financial infrastructure, and ZEC is one of the networks that effectively addresses this challenge [3] Group 3: Future Outlook - The company expects that its participation in the Zcash ecosystem will allow it to benefit from the growing institutional and commercial adoption of digital assets [4] - Reliance believes that Zcash's technology, particularly its privacy features, will contribute to the resilience and growth potential of its treasury portfolio [4]

Core Insights - CaliberCos Inc. has selected Coinbase Global Inc. to provide institutional trading and custody for its Digital Asset Treasury strategy focused on Chainlink's LINK token [1] - CaliberCos claims to be the first Nasdaq-listed company to adopt a treasury reserve policy centered on LINK [2] - The company's stock has experienced a significant decline of over 53% in the past year [2] Company Strategy - Caliber intends to accumulate LINK over time, hold it long-term, and seek yield opportunities, viewing this strategy as complementary to its real estate investments [3] - The Digital Asset Treasury plan aims to provide shareholders with mark-to-market exposure to a blockchain infrastructure asset [2][3] Market Performance - Following the announcement, Caliber's stock initially rose but later fell approximately 4%, trading around $5.94 [1][4] - Coinbase's stock has seen a substantial increase of over 95% in the past year, indicating strong market performance [4]

Core Insights - Artelo Biosciences, Inc. is advancing its clinical pipeline with multiple announcements of clinical data results anticipated in Q3 2025, focusing on treatments for cancer, pain, and neurological conditions [1] Business Highlights - ART26.12 is progressing towards a multi-dose Phase 1 safety study, with positive safety and pharmacokinetics demonstrated in a completed Phase 1 Single Ascending Dose (SAD) study [2][7] - ART27.13 is on track for a Phase 2 readout in Q3 2025, targeting cancer anorexia-cachexia syndrome, a condition with no FDA-approved therapies [3][11] - ART12.11 is showing promise in treating depression and cognitive decline, with plans to initiate human trials in early 2026 [4][8] Financial Results - For Q2 2025, the company reported a net loss of $3.2 million, or $5.61 per share, compared to a net loss of $2.4 million, or $4.52 per share in Q2 2024 [14] - Research and development expenses were $1.9 million for the quarter, up from $1.7 million in the same period in 2024, while general and administrative expenses increased to $1.3 million from $0.8 million [9] Cash and Investments - As of June 30, 2025, cash and investments totaled $2.1 million, with recent funding activities including $0.9 million in convertible notes and a private placement yielding $1.425 million [14] - Subsequent to June 30, 2025, the company completed a PIPE transaction for gross proceeds of $9.475 million, alongside a strategy to invest in the digital currency Solana [14][15]